CN1960734A - 使用10-炔丙基-10-去氮杂氨基蝶呤治疗t细胞淋巴瘤 - Google Patents
使用10-炔丙基-10-去氮杂氨基蝶呤治疗t细胞淋巴瘤 Download PDFInfo
- Publication number
- CN1960734A CN1960734A CNA2005800173160A CN200580017316A CN1960734A CN 1960734 A CN1960734 A CN 1960734A CN A2005800173160 A CNA2005800173160 A CN A2005800173160A CN 200580017316 A CN200580017316 A CN 200580017316A CN 1960734 A CN1960734 A CN 1960734A
- Authority
- CN
- China
- Prior art keywords
- treatment
- propargyl
- pdx
- cell lymphoma
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52159304P | 2004-05-30 | 2004-05-30 | |
| US60/521,593 | 2004-05-30 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210342831.8A Division CN102824346B (zh) | 2004-05-30 | 2005-05-31 | 使用10-炔丙基-10-去氮杂氨基蝶呤治疗t细胞淋巴瘤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1960734A true CN1960734A (zh) | 2007-05-09 |
Family
ID=34971703
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2005800173160A Pending CN1960734A (zh) | 2004-05-30 | 2005-05-31 | 使用10-炔丙基-10-去氮杂氨基蝶呤治疗t细胞淋巴瘤 |
| CN201210342831.8A Expired - Lifetime CN102824346B (zh) | 2004-05-30 | 2005-05-31 | 使用10-炔丙基-10-去氮杂氨基蝶呤治疗t细胞淋巴瘤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210342831.8A Expired - Lifetime CN102824346B (zh) | 2004-05-30 | 2005-05-31 | 使用10-炔丙基-10-去氮杂氨基蝶呤治疗t细胞淋巴瘤 |
Country Status (23)
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102984940A (zh) * | 2010-06-02 | 2013-03-20 | 阿罗斯治疗公司 | 用10-炔丙基-10-去氮杂氨基蝶呤治疗甲氨蝶呤抗性病症的方法 |
| CN103068237A (zh) * | 2010-08-10 | 2013-04-24 | 阿罗斯治疗公司 | 使用10-炔丙基-10-去氮杂氨基蝶呤延长无进展存活期的方法 |
| CN103274943A (zh) * | 2013-05-24 | 2013-09-04 | 苏州明锐医药科技有限公司 | 4-[1-(2-丙炔基)-3,4-二氧代正丁基]苯甲酸酯及其制备方法 |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6835750B1 (en) | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
| US8263354B2 (en) | 2004-05-30 | 2012-09-11 | Sloan-Kettering Institute For Cancer Research | Methods for assessing cancer for increased sensitivity to 10-propargyl-10-deazaaminopterin |
| US20080188479A1 (en) * | 2004-05-30 | 2008-08-07 | Sloan-Kettering Institute For Cancer Research | Methods to Treat Cancer with 10-propargyl-10-deazaaminopterin and Methods for Assessing Cancer for Increased Sensitivity to 10-propargyl-10-deazaaminopterin |
| BRPI0510895A (pt) | 2004-05-30 | 2007-11-27 | Sloan Kettering Inst Cancer | formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t |
| EP2179284B1 (en) | 2007-07-31 | 2016-09-28 | Accera, Inc. | Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function |
| US20090048262A1 (en) * | 2007-08-17 | 2009-02-19 | Allos Therapeutics, Inc. | Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer |
| US9901578B2 (en) | 2007-08-17 | 2018-02-27 | Allos Therapeutics, Inc. | Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer |
| US20100248249A1 (en) * | 2007-08-17 | 2010-09-30 | Allos Therapeutics, Inc. | Methods for Assessing Cancer for Increased Sensitivity to 10-Propargyl-10-Deazaaminopterin by Assessing Egfr Levels |
| US9125881B2 (en) | 2008-07-03 | 2015-09-08 | Accera, Inc. | Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders |
| WO2010022277A2 (en) * | 2008-08-20 | 2010-02-25 | O'connor Owen A | Combination of 10-propargyl-10-deazaaminopterin and bortezomib for the treatment of cancers |
| WO2011096947A1 (en) * | 2010-02-02 | 2011-08-11 | Allos Therapeutics, Inc. | Optically pure diastereomers of 10-propargyl-10-deazaaminopterin and methods of using same |
| WO2013164856A1 (en) | 2012-05-04 | 2013-11-07 | Avra Laboratories Private Limited | A process for preparing intermediates of 10-propargyl-10-deazaaminopterin (pralatrexate) synthesis and the intermediates thereof |
| US11439643B2 (en) | 2015-06-16 | 2022-09-13 | Acrotech Biopharma Inc. | Combination therapy using belinostat and pralatrexate to treat lymphoma |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4393064A (en) * | 1976-03-05 | 1983-07-12 | Sri International | Process and composition for treatment of leukemia and process for preparing the same |
| US4652533A (en) * | 1983-04-28 | 1987-03-24 | Pandex Laboratories, Inc. | Method of solid phase immunoassay incorporating a luminescent label |
| US4843155A (en) * | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
| CA2055813A1 (en) * | 1990-11-20 | 1992-05-21 | Dariush Davalian | Cyclosporin immunoassay |
| US5354751A (en) * | 1992-03-03 | 1994-10-11 | Sri International | Heteroaroyl 10-deazaamino-pterine compounds and use for rheumatoid arthritis |
| US5981592A (en) * | 1995-03-13 | 1999-11-09 | Loma Linda University Medical Center | Method and composition for treating cystic fibrosis |
| US6323205B1 (en) * | 1996-07-17 | 2001-11-27 | Sloan-Kettering Institute For Cancer Research | Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors |
| US6028071A (en) * | 1996-07-17 | 2000-02-22 | Sloan-Kettering Institute For Cancer Research | Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors |
| GB0128510D0 (en) * | 2001-11-28 | 2002-01-23 | Novartis Ag | Organic compounds |
| BRPI0510895A (pt) * | 2004-05-30 | 2007-11-27 | Sloan Kettering Inst Cancer | formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t |
-
2005
- 2005-05-31 BR BRPI0510895-0A patent/BRPI0510895A/pt not_active Application Discontinuation
- 2005-05-31 ZA ZA200609266A patent/ZA200609266B/xx unknown
- 2005-05-31 WO PCT/US2005/019170 patent/WO2005117892A1/en not_active Ceased
- 2005-05-31 US US11/141,868 patent/US7622470B2/en not_active Expired - Lifetime
- 2005-05-31 ME MEP-2008-310A patent/ME01087B/me unknown
- 2005-05-31 SI SI200530392T patent/SI1750716T1/sl unknown
- 2005-05-31 EP EP05756183A patent/EP1750716B1/en not_active Expired - Lifetime
- 2005-05-31 US US11/568,254 patent/US7939530B2/en active Active
- 2005-05-31 HR HR20080569T patent/HRP20080569T3/xx unknown
- 2005-05-31 CN CNA2005800173160A patent/CN1960734A/zh active Pending
- 2005-05-31 CA CA2565968A patent/CA2565968C/en not_active Expired - Lifetime
- 2005-05-31 CN CN201210342831.8A patent/CN102824346B/zh not_active Expired - Lifetime
- 2005-05-31 WO PCT/US2005/019169 patent/WO2005117891A1/en not_active Ceased
- 2005-05-31 AT AT05756183T patent/ATE405272T1/de active
- 2005-05-31 AU AU2005249516A patent/AU2005249516B2/en not_active Expired
- 2005-05-31 RS RSP-2008/0470A patent/RS50622B/sr unknown
- 2005-05-31 NZ NZ551082A patent/NZ551082A/en not_active IP Right Cessation
- 2005-05-31 JP JP2007515512A patent/JP5005532B2/ja not_active Expired - Lifetime
- 2005-05-31 MX MXPA06013559A patent/MXPA06013559A/es active IP Right Grant
- 2005-05-31 DK DK05756183T patent/DK1750716T3/da active
- 2005-05-31 PT PT05756183T patent/PT1750716E/pt unknown
- 2005-05-31 ES ES05756183T patent/ES2313365T3/es not_active Expired - Lifetime
- 2005-05-31 KR KR1020117012373A patent/KR101189693B1/ko not_active Expired - Lifetime
- 2005-05-31 DE DE602005009176T patent/DE602005009176D1/de not_active Expired - Lifetime
- 2005-05-31 NZ NZ576849A patent/NZ576849A/en not_active IP Right Cessation
- 2005-05-31 PL PL05756183T patent/PL1750716T3/pl unknown
-
2006
- 2006-12-22 NO NO20065971A patent/NO337276B1/no unknown
-
2009
- 2009-10-21 US US12/603,117 patent/US8299078B2/en not_active Expired - Lifetime
-
2012
- 2012-10-29 US US13/663,234 patent/US20130053391A1/en not_active Abandoned
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102984940A (zh) * | 2010-06-02 | 2013-03-20 | 阿罗斯治疗公司 | 用10-炔丙基-10-去氮杂氨基蝶呤治疗甲氨蝶呤抗性病症的方法 |
| CN102984940B (zh) * | 2010-06-02 | 2016-01-13 | 阿罗斯治疗公司 | 用10-炔丙基-10-去氮杂氨基蝶呤治疗甲氨蝶呤抗性病症的方法 |
| CN103068237A (zh) * | 2010-08-10 | 2013-04-24 | 阿罗斯治疗公司 | 使用10-炔丙基-10-去氮杂氨基蝶呤延长无进展存活期的方法 |
| CN103274943A (zh) * | 2013-05-24 | 2013-09-04 | 苏州明锐医药科技有限公司 | 4-[1-(2-丙炔基)-3,4-二氧代正丁基]苯甲酸酯及其制备方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3802534B1 (en) | Tricyclic heterocyclic compounds as sting activators | |
| TWI268923B (en) | N6 heterocyclic 8-modified adenosine derivatives | |
| CN117247382A (zh) | 吡啶并嘧啶酮化合物的晶型 | |
| JP2021038241A (ja) | N−(3,5−ジメトキシフェニル)−n’−(1−メチルエチル)−n−[3−(1−メチル−1h−ピラゾール−4−イル)キノキサリン−6−イル]エタン−1,2−ジアミンを含んでなる医薬組成物 | |
| US20130053391A1 (en) | Treatment of T-Cell Lymphoma using 10-propargyl-10-deazaaminopterin | |
| CN104066723B (zh) | 1-(芳基甲基)-5,6,7,8-四氢喹唑啉-2,4-二酮和相关化合物及其应用 | |
| EA027990B1 (ru) | Замещенные (2r,3r,5r)-3-гидрокси(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты | |
| US20110104186A1 (en) | Small molecule immunopotentiators and assays for their detection | |
| CN113717245A (zh) | 含有2,8,9-三取代-9h-嘌呤结构片段的egfr降解剂及其盐和应用 | |
| Weis et al. | L-ribofuranosyl nucleosides | |
| CN101454309B (zh) | 焦谷氨酸衍生物的合成和用途 | |
| CN114539278A (zh) | IL-15抑制剂Neoprzewaquinone A,及其筛选方法和应用 | |
| EP3740287B1 (en) | Treatments for cachexia | |
| CN115038701A (zh) | Jak抑制剂的晶型及其应用 | |
| CN1188413C (zh) | 治疗疼痛的化合物 | |
| CN113662945B (zh) | 用于治疗乙型肝炎的组合 | |
| CN120737091B (zh) | 一种以7-脱氮鸟嘌呤为骨架的化合物、药物组合物及用途 | |
| CN106146408B (zh) | 2,5,6位取代嘧啶酮衍生物的制备方法及其作为抗乙肝病毒药物的应用 | |
| JP2002536448A (ja) | 治療用ヌクレオシド化合物 | |
| CN121041265A (zh) | 化合物在制备抗结直肠癌腹膜转移药物中的应用 | |
| JPH0395166A (ja) | イソキサゾロン誘導体含有脳機能改善剤 | |
| HK1177901B (en) | Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin | |
| WO2021102343A1 (en) | Solid dose pharmaceutical composition | |
| CN114560904A (zh) | IL-15抑制剂Diosgenin,及其筛选方法和应用 | |
| HK40050938A (en) | Tricyclic heterocyclic compounds as sting activators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20070509 |